Outstanding international @WIN_Consortium MTB with discussion of cases presented today by Dr. Amin Abyad at @BurjeelMediCity and @SewantiLimaye in Mumbai including cholangiocarcinoma with Met amplification, RBM10 mutation, FANCM and KDR truncating mutations and p53 LOF mutation, testicular leiomyosarcoma with NF1 mutation, and adenoid cystic carcinoma with lung and liver metastases, Kit, PDGFRA, and KDR amplification, EP300, KMT2A, PPP2R1A mutations among others. We discussed various driver molecular alterations that may be amenable to targeted therapy or immunotherapy combinations. Today’s participants from US, India, Spain, UAE, and China among others. @WIN_Consortium@Dr_R_Kurzrock@VivekSubbiah@alshamsi2000
Great conversation this afternoon with John Tarantino about Precision Oncology and collaboration opportunities with the @WIN_Consortium in cancer personalized medicine
My personal AI Avatar makes its debut with a message about Precision Oncology, the WIN Consortium and the recent 2026 WIN Symposium in Rhode Island earlier this October.
This video is the English language version.
I was inspired to do this by my colleagues Professor Ning Liao and Professor Charles Balch who along with Dennis Lam organized a fantastic ISOPT meeting in China with some content translated into different languages after the meeting.
I was also inspired by my Indiana University Physician MBA Program discussions on the role of AI in medicine now and in the future and finally by my Harvard Data Science Review Build Your Agent Intensive Course this October.
@WIN_Consortium@Dr_R_Kurzrock@SewantiLimaye@LiaTsimberidou@charlesbalchmd@KelleyBizMed@harvard_data@VivekSubbiah@bcarneiro7@curijoey@RueterJens@billdahutmd@jrgralow@AmericanCancer@ASCO@theNCI@AACR@AACRPres@AACI_Cancer
⭐️Congrats to @weldeiry@Dr_R_Kurzrock & @WIN_Consortium for pulling off one of the best precision oncology meetings.
⭐️Global faculty from every continent, the who’s‑who of precision oncology in one room + a platform that sparks real debate+ discussion+ collaboration. The live molecular tumor board was #Precision oncology at its finest @OncoAlert@oncodaily@SewantiLimaye
2026 WIN Symposium Panel at the Rhode Island Convention Center in Providence, RI on October 2, 2026
Industry Perspectives: Genomic Profiling, Next-Generation Drugs & Precision Oncology
Moderator:
Bob Cormier, President and CEO of the Rhode Island Life Science Hub, Providence, RI, USA
Panelists:
Zachary Boyd, MS, PhD, VP, Precision Medicine & Companion Diagnostics, J&J, Thousand Oaks, CA, USA
John Tarantino, JD, CEO, Iylon, Providence, RI, USA
David Spetzler, MS, PhD, MBA, President, Caris Life Sciences, Paradise Valley, AZ, USA
Navid Alipour, JD, MBA, Co-Founder and CEO, Curematch, San Diego, CA, USA
Nesrin Erkol, PhD, CEO, Vaccizone Biotechnology, Turkey
Bradley Sander, CEO, p53-Therapeutics, Providence, RI, USA
Emile Youssef, MD, PhD, CMO, p53-Therapeutics, Providence, RI, USA
Although requested and supported by the Chair of the WIN Consortium and a Letter of Support from United States Senator Jack Reed from Rhode Island, Professor Nesrin Erkol, who was invited, could not get an interview or obtain a Visa to travel from Turkey to the United States to participate in the 2026 WIN Symposium in Rhode Island as a Symposium Sponsor, Poster Presenter, and panelist for the Industry Perspectives Panel. Professor Erkol was planning to provide a global industry perspective and has expressed interest in being part of the RI biotech ecosystem to promote the operations and impact of her company Vaccizone Biotechnology.
youtu.be/eaYS0y5RKiA@WIN_Consortium@VivekSubbiah@AACRPres@LiaTsimberidou@bcarneiro7@targetcancer@Dr_R_Kurzrock@curijoey@oncodaily@NCIDirector@jrgralow@CliffordHudis@ASCO@BrownUniversity@BrownUnivHealth@rwsobol@SewantiLimaye@LussierY@DrRoyHerbst@SenduraiMani@LiangChengMD@AACI_Cancer@AmericanCancer@carisls@GuardantHealth@TempusAI@FoundationATCGyoutu.be/eaYS0y5RKiA